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ﺔﺻﻼﺨﻟا:
 ﺖﻨﻤﻀﺗ ﺔﯿﺿﺮﻋ ﺔﯿﻌﻄﻘﻣ ﺔﺳارد ﻲﻓ28 ﺐﻠﻘﻟا ﺔﺣاﺮﺟو ضاﺮﻣﻷ ﻒﺠﻨﻟا ﺰﻛﺮﻣ ﻲﻓ ﺔﯿﺟﺎﺘﻟا ﻦﯿﯾاﺮﺸﻟا ةءﺎﻔﻛ مﺪﻌﺑ ﺎﺑﺎﺼﻣ ﺎﻀﯾﺮﻣ
 لوﻷا نﻮﻧﺎﻛ ﺔﯾﺎﻐﻟ لوﻷا ﻦﯾﺮﺸﺗ ﻦﻣ ةﺮﺘﻔﻠﻟ2011 . ﻦﯿﺘﺌﻓ ﻰﻟإ ﻰﺿﺮﻤﻟا عزﻮﺗ ، رﺎﻘﻋ مﺪﺨﺘﺴﺗ ﺔﺌﻓplavix رﺎﻘﻋ مﺪﺨﺘﺴﺗ ﺔﯿﻧﺎﺜﻟا ﺔﺌﻔﻟاو
plagrineلا زﺎﮭﺠﺑ ﺞﺋﺎﺘﻨﻟا ﻞﯿﻠﺤﺗ ﻢﺗو ﻦﯿﺘﻨﯿﻌﻟا ﻼﯿﻜﻟ ﺔﯾﻮﻣﺪﻟا تﺎﺤﯿﻔﺼﻟا ﻊﻤﺠﺗ ةءﺎﻔﻛ سﺎﯿﻗ ﻢﺗوmultiplate machine ﻞﯿﻠﺤﺗ ﻢﺗو
 ماﺪﺨﺘﺳﺎﺑ ﺎﯿﺋﺎﺼﺣإ ﺞﺋﺎﺘﻨﻟاﺞﻣﺎﻧﺮﺑspss version 19) ( ﺔﺠﯿﺘﻨﻟﺎﺑ ﻦﯿﯾرﺎﻘﻌﻟا ﻦﯿﺑ قﺮﻓ ﺪﺟﻮﯾ ﻻ ﮫﻧا ﺞﺋﺎﺘﻨﻟا تﺮﮭظأو) ﺖﺤﺗ ﺔﺣﺎﺴﻤﻟا
 ﻲﻨﺤﻨﻤﻟاAUC ( ﻦﯿﺘﻨﯿﻌﻟا ﻼﻛ ﻲﻓ)plavix and plagrine ( ةرﻮﻄﺨﻟا ﻞﻣاﻮﻋ نإ ﺞﺋﺎﺘﻨﻟا تﺮﮭظأ ﻚﻟﺬﻛو) ﺲﻨﺠﻟا ،ﺮﻜﺴﻟا، ﻂﻐﻀﻟا
،ﻦﯿﺧﺪﺘﻟا،نﻮھﺪﻟا ( ﻦﯿﺘﻋﻮﻤﺠﻤﻟا ﻼﻛ ﻲﻓ ﺞﺋﺎﺘﻨﻟا ﻰﻠﻋ ﺮﺛﺆﺗ ﻢﻟ.
Abstract
Cardiovascular disease remains the main cause of mortality. Antiplatelet therapy is the main drug
use in the management of coronary artery disease. Several million of people receivedcolpidogril,
however  the cost of the drug that might 3-4 dollars daily for the brand company sanofi .pharmacies
start to sell cheaper generic from Indian origin .assessment of platelet function after two drugs(plavix
and plagrine) by  multiple electrode platelet aggregometry (MEA) shows no difference of both drugs
on the multiplate activity,this is assessted by prospective cross sectional study included 28 patients
randomized to receive either plavix or plagrine, there is no significant differences  regarded the effects
of some risk factors in outcome in both group plavix and plagrine.
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INTRODUCTION:
Atherosclerosis is the reason behind coronary artery disease which is the
leading cause of mortality and morbidity for human being  worldwide(1).Platelets have
been shown to play a central role in the pathogenesis of atherosclerosis(2).
clopidogerl is the second common most widely sold drug in the world(3) used in
the management of CAD and stroke (4) .The main anti plattlet action of clopidogrel is
theinopyridine class inhibit of   ADP P2Y12 receptor  responsible for aggregation (5).
Several millions of people received the drug daily . The brand companies sold
more than 6 billion dollars in one year. However a lot of people could not offer the
drug that might cost 3-4 dollars daily(6).
In 2006 many companies started to manufacture  the drug generics out of the
legal pharmaceutical patent from the brand manufacturer (plavix ® sanofi
aventis,french).this led to many legal conflicts' and ended with proposed settlement(7).
Several methods used to analyze platelets function in the whole blood; One of
this methods is multiple electrodes platelet aggregometry (MEA) which is easy and
reproducible and sensitive method for measuring platelet aggregation and evaluation
of anti platelet drugs especially clopidogrel (8).
Assessment of bioavailability of the anti platelet therapy (measured by the area
under the curve) is crucial because it might predict stent thrombosis ((9) which is the
true night mares for the interventionist.
The Iraqi pharmacies started to sell clopidogrel with different generics(plagerin,
plavidosa …etc.) with great variable prices (Table 1)
Table 1: List of interchangeable brand or generic drugs
Unit description Price,USD
Pladogrel (Indonesia)
Pladogrel 75mg ×30s $ 30.29
Plagril(myanmmar,peru)
Plagril capsule/tablet/75mg(10unit) $ 0.77
Plagril 75mg TAB/10 $ 0.71
Plagril 75mg ×2×7s $  0.71
75mg ×10s
Plagrin(Bangladesh)
Plahasan 75mg×1 blister×10 tablet
Planor(turkey)
Plaraz 75
Platec(Indonesia)
Platec 75mg ×3×10s $ 27.23
Platfree(Myanmar)
Platfree capsule/tablet/75mg(10units) $ 1.12
Platfree 75mg TAB /10 $ 2.90
75mg ×10s $ 2.90
Platfrin(india)
Platfrin capsule/tablet/75mg(10units) $ 1.20
Platfrin capsule/tablet/150mg(10units $ 1.40
Platfrin 75 TAB/10 $ 1.20
Platfrin 150 TAB/10 $ 1.40
75mg ×10s $ 1.20
150mg ×10s $ 1.40
Platloc(india)
75mg ×10s $ 0.64
Platloc 75mg  TAB/10 $ 0.64
AIM OF THE STUDY:
Aprospective cross sectional study to assess the platelet reactivity in response to
clopidogrel after administration of two different drug formulation french brand and
cheaper Indian generic. By applying MEA technique using multiplate® machine.
MATERIALS AND METHODS:
This study conducted in Al-Najaf cardiac center in Al-Sader teaching medical
city from November 2011 till December 2011. The total number was 28 (21males, 7
females); 13 patients tested for plavix. Another 15 group tested for plagerine.
The two groups (plavix and plagerin) tested for platelet aggrregabilty and drug
bioavailablity measured by the area under the curve versus time,target level (53-122)
unit using multiple electrodes platelet aggregometry (MEA).
To ensure that both drugs reach the steady state level, samples collected after a
duration of time -at least-more than 10 days following administration of the drugs.
The results were expressed as mean ± SD and analyzed by applying independent
t-test. Significance variation was considered when (p≤ 0.05), =0.05 using SPSS
program version 19.
RESULTS:
There was no statistical difference between plavix group (11.000+-6.733) and
plagerin group (5.234+-1.35) with p- value =0.299. (Table 2).
This results did not reach level of significance regarding the effect of risk
factors (hypertension, diabetes and smoking) on the outcome neither in plavix
group(Table 3), nor in plagerine group (Table 4).
There was linear relationship between isolated risk factors and AUC regarding
BMI (Figure 1) and age (Figure 2).
We find the mean area under the curve among those using plavix group was
more than that in plagerine group (Figur3) but this did not reach level of significance.
Table 2: Comparison of mean area of platelet aggregation (Unit) between
patients on plavix and plagerine.
AUC No. Mean ± SD St.error mean p-
value
95%confidence interval
of the difference
Lower Upper
plavix 13 11.000 ± 6.733 1.8674 0.299 - 2.2524 7.052
plagerine 15 5.234 ± 1.351 1.3515 - 2.373 7.173
Table 3: Mean area in unit between patients receiving plavix according to some
risk factors:
Risk factor No. Mean area (u) of plavix ±
S.E
p-value
Gender
M
F
9
4
10.660 ± 1.950
11.750 ± 4.714
0.802
Diabetes mellitus
Yes
No
3
10
13.670 ±  3.710
10.200 ±  2.190
0.450
Hypertension
Yes
No
6
7
12.667 ±2.530
9.570 ± 2.750
0.433
Smoking
Yes
No
3
10
7.660 ±1.760
12.000 ±2.314
0.350
Triglyceride
Yes
No
7
6
10.714 ± 2.588
11.333± 2.951
0.877
Table 4: Mean area in unit between patients receiving plagerine according to
some risk factors:
Risk factor No. Mean area (u) of plavix ±
S.E
p-value
Gender
M
F
12
3
8.667 ± 1.563
8.330 ± 3.179
0.926
Diabetes mellitus
Yes
No
4
11
10.000 ± 1.201
8.500 ± 1.447
0.793
Hypertension
Yes
No
2
13
6.000 ± 4.000
9.000 ± 1.467
0.471
Smoking
Yes
No
2
13
10.500 ± 1.500
8.307 ± 1.541
0.600
Triglyceride
Yes
No
3
12
5.000 ± 1.527
9.500 ± 1.559
0.193
Figure 1: linear regression relationship between body mass index( BMI) and
area under the curve (AUC) in unit.
Figure 2: linear regression relationship between age and area under the curve
(AUC) in unit.
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Figure 3: mean area of platelet aggregation in unit between patient receiving
plavix and plagreine in relation to risk factor.
DISCUSSION:
Blood sample of  28 patients with ischemic heart disease were included for
estimated the platelet aggregability after two different brands of drug (plavix and
plagrine ); tested  by using the multiple electrode platelet aggregometry (MEA), the
results demonstrated no statistical differences between plavix group (mean ± SD) was
(11.00 ± 6.733) with P- value equal to 0.299 as in( Table 2).
Regarding isolated factors (gender, diabetes, hypertension, and smoking), sex
had no effect on the mean area under the curve.
The curve in plavix arm, which is consistent with cure trial (10), this also
occurred in the plagrine side.
Diabetes is accompanied by platelete function disorders hyporesponsiveness to
clopidogril (11)..
However this is consistent with our study (13.67 ± 3.710) versus (10.00 ±
2.190) in plavix group and (10.00 ± 1.201) versus (8.500 ± 1.447) in patients with
plagrine group.
Both drugs formulation gave good level regarding bioavailabity of the
antiplatlet therapy, which represent presence of clopidogrel active ingredient that gave
adequate test result regarding platelet inhibition.
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Also our result showed the mild deference regarding area under the curve(
AUC), which was little higher in plavix group, which is not reach level of
significance.
CONCLUSION:
Plagerine is as effective as plavix regarding the anti plattlet effect and can be
used as alternative and cheaper therapy for pericutanus coronary intervention (PCI)
and other indications for antiplatlet.
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